Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Shots: The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community The major announcement…

BySenior EditorJanuary 19, 2023

TOP 20

Top 20 Biopharma M&A of 2022 by Total Deal Value

Shots: Mergers and Acquisitions are among the predominant elements of the Biopharma Industry. Owing to the repercussions of the Russia-Ukraine war and the ongoing COVID-19 pandemic, the IPOs, public markets, anti-trust law reforms by the US FTC, and M&As among others were relatively low in the biopharma sector in the year 2022 In the year…

ByPrince GiriJanuary 11, 2023

INSIGHTS+

PharmaShots’ Most Read News of 2022

The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2022 1. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…

BySenior EditorJanuary 2, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in November 2022

Shots: The EMA approved 4 New Chemical Entity (NCE) and 4 Biologic Drugs in November 2022, leading to treatments for patients and advances in the healthcare industry In November 2022, the major highlights drugs were Skyrizi's approval for active crohn's disease, Beyfortus for RSV lower respiratory tract disease PharmaShots has compiled a list of a…

BySenior EditorDecember 28, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in August 2022

The US FDA approved 4 NDAs and 1 BLA in August 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 47 novel products in 2022 In August 2022, the major highlights drugs were Calquence's approval for blood cancer, Imbruvica (ibrutinib) for chronic graft versus host disease in…

BySenior EditorSeptember 15, 2022

TOP 20

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Shots: Oncology focuses on the study, diagnosis, prevention, and treatment of cancer based on the treatment option and it’s divided into 3 major areas including medical oncology, radiation oncology, and surgical oncology The advancements in cell and gene therapies have provided pharmaceutical companies with a unique set of ground-breaking tools for the development of more…

ByPrince GiriSeptember 8, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2022

The US FDA approved 2 NDAs and 2 BLA in June 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 37 novel products in 2022 In June 2022, the major highlights drugs were Amvuttra's approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis, Skyrizi for active Crohn's disease, Olumiant…

BySenior EditorJuly 21, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of April 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Alvotech resolved a European patent dispute with…

BySenior EditorMay 5, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in March 2022

The US FDA has approved 9 NDAs and 1 BLAs in Mar 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 20 novel products in 2022 In Mar 2022, the major highlights drugs were Adlarity for Alzheimer's Disease, Rinvoq for Ulcerative Colitis, Ztalmy for CDKL5 Deficiency Disorder…

BySenior EditorApril 21, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Top 20 Biopharma M&A of 2022 by Total Deal Value

PharmaShots’ Most Read News of 2022

Insights+: EMA Marketing Authorization of New Drugs in November 2022

Insights+: The US FDA New Drug Approvals in August 2022

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Insights+: The US FDA New Drug Approvals in June 2022

Insights+ Key Biosimilars Events of April 2022

Insights+: The US FDA New Drug Approvals in March 2022

Top 20 BioPharma Companies based on 2021 Total Revenue

Contact US

FOLLOW US